Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)

Merck Sharp & Dohme (MSD)

Status and phase

Completed

Phase 2

Conditions

Urinary Tract Infections

Bacterial Pneumonia

Soft Tissue Infections

Treatments

Drug: MK0826, ertapenem sodium /Duration of Treatment: 14 Days

Drug: Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days

Study type

Interventional

Funder types

Industry

Identifiers

NCT00451386

0826-036

2007_525

Details and patient eligibility

About

This study will investigate the safety and efficacy of ertapenem versus ceftriaxone in pediatric patients with urinary tract infections, skin infections, or community-acquired pneumonia.

Sex

All

Ages

3 months to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with UTI must have white blood cells and bacteria in the urine with bladder catheterization or urologic abnormality, kidney infection or both
Patients with SSTI must have a recent infection
Patients with CAP must have a chest x-ray indicating bacterial pneumonia and a fever

Exclusion criteria

Patients with complete urinary tract blockage or kidney abscess
Patients with infected burn wounds, bone infection, or bacterial arthritis
Patients on mechanical ventilation or those with cystic fibrosis, chronic lung disease or puss in the space between the chest wall and lung